CNBC February 21, 2025
Ashley Capoot

Key Points

– 23andMe CEO Anne Wojcicki and New Mountain Capital have submitted a proposal to take the company private.

– They are offering to buy all outstanding shares in cash for $2.53 per share, or an equity value of approximately $74.7 million.

– The deal still needs to be approved by 23andMe’s special committee of independent directors.

23andMe CEO Anne Wojcicki and New Mountain Capital have submitted a proposal to take the embattled genetic testing company private, according to a Friday filing with the U.S. Securities and Exchange Commission.

Wojcicki and New Mountain have offered to acquire all of 23andMe’s outstanding shares in cash for $2.53 per share, or an equity value of approximately $74.7 million. The company’s stock...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Investments, Pharma / Biotech, Trends
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
Stakeholder Management and Interoperability of Biosimilars
Pharma Pulse 2/21/25: RWE in Medical Research and Drug Development, Inhaled Antibody Therapy for RSV & more
FDA approves first rapid-acting insulin biosimilar for diabetes
Pharma Pulse 2/20/25: Popping the Gross-to-Net Bubble, Prompting Better Care with Question Prompt Lists & more

Share This Article